Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models,
perifosine has an independent cytotoxic potential but also synergizes well with other …

Introduction: Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …

Abstract The PI3K/Akt/mTOR pathway is aberrantly active in most human cancers and
contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular …

Perifosine treatment exhibits a complex molecular response including the inhibition of Akt or
the induction of apoptosis via clustering of death receptors in lipid rafts. However, the …

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase
(PI3K), is known to play an important role in antiapoptotic signaling and has been implicated …

Perifosine is an Akt inhibitor displaying strong antineoplastic effects in human tumor cell
lines and is currently being tested in phase II clinical trials for treatment of major human …

Perifosine, which belongs to the novel class of antitumoral agents alkylphospholipids, is
currently undergoing phase II clinical evaluation (van Blitterswijk & Verheij, 2008). Although …

Perifosine (NSC 639966; Keryx Biopharmaceuticals, New York, NY) is a synthetic novel
alkyl-lysophospholipid, a new class of anti-tumor agents which targets cell membranes and …

Purpose: It is critical to develop methods to quantify the early pharmacodynamic effects of
targeted therapeutics in vivo to make drug development more efficient and ensure …

9540 Background: Perifosine is a synthetic alkylphospholipid which inhibits Akt activity and
also has been reported to affect the JNK and MAPK signaling pathways. Single agent trials …